IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.
Antiestrogens are effective therapies for the management of many estrogen receptor-alpha (ER)-positive breast cancers. Nonetheless, both de novo and acquired resistance occur and remain major problems in the clinical setting. IFNgamma is an inflammatory cytokine that induces the expression and function of IFN regulatory factor 1 (IRF1), a tumor suppressor gene that can increase antiestrogen responsiveness. We show that IFNgamma, but not IFNalpha, IFNbeta, or fulvestrant (ICI; ICI 182,780; Faslodex), induces IRF1 expression in antiestrogen-resistant MCF7/LCC9 and LY2 cells. Moreover, IFNgamma restores the responsiveness of these cells to fulvestrant. Increased IRF1 activation suppresses NF-kappaB p65 (RELA) activity, inhibits the expression of prosurvival (BCL2, BCL-W), and induces the expression of proapoptotic members (BAK, mitochondrial BAX) of the BCL2 family. This molecular signaling is associated with the activation of signal transducer and activator of transcription 1 and leads to increased mitochondrial membrane permeability; activation of caspase-7 (CASP7), CASP8, and CASP9; and induction of apoptosis but not autophagy. Whereas antiestrogen-resistant cells are capable of inducing autophagy through IFN-mediated signaling, their ability to do so through antiestrogen-regulated signaling is lost. The abilities of IFNgamma to activate CASP8, induce apoptosis, and restore antiestrogen sensitivity are prevented by siRNA targeting IRF1, whereas transient overexpression of IRF1 mimics the effects of IFNgamma treatment. These observations support the exploration of clinical trials combining antiestrogens and compounds that can induce IRF1, such as IFNgamma, for the treatment of some ER-positive breast cancers.
Ning
Yanxia
Y
Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC 20057, USA.
Riggins
Rebecca B
RB
Mulla
Jennifer E
JE
Chung
Haniee
H
Zwart
Alan
A
Clarke
Robert
R
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D020169:Caspases / Q000378:metabolism / Q000502:physiology; D004353:Drug Evaluation, Preclinical; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000235:genetics*; D004357:Drug Synergism; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D000077267:Fulvestrant; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D050856:Interferon Regulatory Factor-1 / Q000235:genetics / Q000378:metabolism; D007371:Interferon-gamma / Q000494:pharmacology*; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D050794:STAT1 Transcription Factor / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; C494257:IRF1 protein, human; D050856:Interferon Regulatory Factor-1; D016328:NF-kappa B; D019253:Proto-Oncogene Proteins c-bcl-2; D050794:STAT1 Transcription Factor; C494079:STAT1 protein, human; D000077267:Fulvestrant; D004958:Estradiol; D007371:Interferon-gamma; D020169:Caspases
Br J Cancer. 2000 Nov;83(10):1380-6
11044365
Cancer Res. 2004 Jun 1;64(11):4030-9
15173018
Br J Cancer. 1987 Mar;55(3):255-7
3567059
Cancer. 1987 Nov 15;60(10):2419-23
3664427
Mol Cancer Ther. 2005 Jan;4(1):33-41
15657351
Carcinogenesis. 2005 Sep;26(9):1527-35
15878912
Mol Cell Biol. 2003 Oct;23(19):6887-900
12972607
Science. 1994 Jun 3;264(5164):1415-21
8197455
Mol Cell Biol. 1996 Oct;16(10):5546-56
8816467
Vitam Horm. 2005;71:201-37
16112269
FASEB J. 2010 Jun;24(6):2040-55
20154269
Oncogene. 2003 Oct 20;22(47):7316-39
14576841
Oncogene. 2004 Feb 5;23(5):1125-35
14762441
Endocrinology. 1985 Oct;117(4):1409-17
4029083
Nature. 1995 Aug 17;376(6541):596-9
7637809
Proc Natl Acad Sci U S A. 1992 May 1;89(9):4037-41
1570330
Pharmacol Rev. 2001 Mar;53(1):25-71
11171938
J Endocrinol. 1989 Jul;122(1):331-40
2769157
Annu Rev Biochem. 1987;56:727-77
2441659
Breast Cancer Res Treat. 2001 Jul;68(2):127-38
11688516
Cancer. 2003 Jul 15;98(2):229-38
12872340
Cancer Res. 1997 Aug 15;57(16):3486-93
9270017
Breast Cancer Res Treat. 1994;32(1):39-47
7819584
Biochem Biophys Res Commun. 2000 Mar 5;269(1):31-4
10694472
Int J Oncol. 2006 Jan;28(1):67-76
16327981
Bioinformatics. 2005 Jul 1;21(13):2933-42
15860560
Lancet. 1995 Jan 7;345(8941):29-30
7799704
J Biol Chem. 1996 Mar 8;271(10):5790-4
8621447
Oncogene. 2000 Jul 13;19(30):3372-83
10918594
Oncogene. 2004 Nov 18;23(54):8743-55
15467738
J Clin Invest. 2001 Feb;107(3):241-6
11160144
PLoS One. 2010 Jan 06;5(1):e8604
20062536
J Immunol. 2000 Apr 1;164(7):3512-8
10725705
Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59
18097445
EMBO J. 1997 Jan 15;16(2):406-16
9029159
EMBO J. 1998 Jul 1;17(13):3660-8
9649436
Proc Natl Acad Sci U S A. 1990 Sep;87(17):6883-7
2395882
Lancet. 1992 Jan 4;339(8784):1-15
1345950
Mol Cell Biol. 1997 Jul;17(7):3629-39
9199297
Int J Cancer. 2003 Jul 10;105(5):607-12
12740907
J Interferon Cytokine Res. 2005 Oct;25(10):587-94
16241857
Br J Cancer. 2004 Mar;90 Suppl 1:S11-4
15094759
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Nucleic Acids Res. 1997 Nov 1;25(21):4346-54
9336467
J Biol Chem. 2000 Mar 3;275(9):6499-508
10692454
Oncogene. 2007 Sep 27;26(44):6420-30
17452973
Cancer Res. 2004 Nov 15;64(22):8381-8
15548708
Cancer Res. 1989 May 15;49(10):2698-702
2469536
Nature. 1996 Aug 29;382(6594):816-8
8752276
Cancer Res. 2002 Jun 15;62(12):3428-37
12067985
Cell. 1994 Jun 17;77(6):829-39
8004672
J Steroid Biochem. 1988 Oct;31(4B):645-53
3199810
Cancer Res. 1993 Jan 15;53(2):283-90
8380254
Biochem Biophys Res Commun. 2006 Apr 21;342(4):1249-56
16516145